Trial Profile

The international, non-interventional, Coptimze trial of glatiramer acetate injection in relapsing-remitting multiple sclerosis.

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 11 Sep 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Glatiramer acetate (Primary)
Indications Multiple sclerosis
Focus Therapeutic Use
Acronyms Coptimize
Sponsors Teva Pharmaceutical Industries

Most Recent Events

15 Apr 2011 Preliminary results have been presented at AAN-2011 according to a Teva Pharmaceutical Industries media release; results were also reported in the media release.
15 Apr 2011 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com